3 Safest Stocks to Buy Now
With the S&P 500 now in correction and stocks selling…
Buy
72
ADMA Quote, Financials, Valuation and Earnings
Last price:
$18.24
Seasonality move
:
12.37%
Day range:
$17.64 - $18.62
52-week range:
$5.88 - $23.64
Dividend yield:
0%
P/E ratio:
21.84x
P/S ratio:
10.18x
P/B ratio:
12.14x
Volume:
2.4M
Avg. volume:
2.6M
1-year change:
186.1%
Market cap:
$4.2B
Revenue:
$426.5M
EPS (TTM):
$0.82
Analysts' Opinion
-
Consensus RatingADMA Biologics has received a consensus rating of Buy. The company's average rating is a Buy based on 4 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $25.27, ADMA Biologics has an estimated upside of 41.11% from its current price of $17.91.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $19.09 representing 100% downside risk from its current price of $17.91.
Fair Value
-
According to the consensus of 4 analysts, ADMA Biologics has 41.11% upside to fair value with a price target of $25.27 per share.
ADMA vs. S&P 500
-
Over the past 5 trading days, ADMA Biologics has overperformed the S&P 500 by 10.68% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
ADMA Biologics does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
ADMA Biologics has grown year-over-year revenues for 23 quarters straight. In the most recent quarter ADMA Biologics reported revenues of $117.5M.
Earnings Growth
-
ADMA Biologics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter ADMA Biologics reported earnings per share of $0.46.
Enterprise value:
4.2B
EV / Invested capital:
9.98x
Price / LTM sales:
10.18x
EV / EBIT:
30.13x
EV / Revenue:
9.87x
PEG ratio (5yr expected):
--
EV / Free cash flow:
53.37x
Price / Operating cash flow:
47.76x
Enterprise value / EBITDA:
28.86x
Gross Profit (TTM):
$219.6M
Return On Assets:
51.06%
Net Income Margin (TTM):
46.35%
Return On Equity:
93.41%
Return On Invested Capital:
60.85%
Operating Margin:
32.6%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $154.1M | $258.2M | $426.5M | $73.9M | $117.5M | |
| Gross Profit | $35.3M | $88.9M | $219.6M | $31.1M | $63.3M | |
| Operating Income | -$39.4M | $21.6M | $139M | $14.2M | $38.3M | |
| EBITDA | -$39.5M | $5.1M | $145.8M | -$9.3M | $37.6M | |
| Diluted EPS | -$0.34 | -$0.13 | $0.82 | -$0.08 | $0.46 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $153.7M | $208.7M | $270.4M | $257M | $331.4M | |
| Total Assets | $207.7M | $276.3M | $348.5M | $329.2M | $488.7M | |
| Current Liabilities | $19.9M | $30.4M | $39.3M | $49.8M | $55.5M | |
| Total Liabilities | $119.4M | $135.1M | $196.5M | $194M | $139.7M | |
| Total Equity | $88.2M | $141.2M | $152M | $135.2M | $349M | |
| Total Debt | $93M | $94.9M | $142.8M | $130.6M | $72.3M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$85.6M | -$16.2M | $86.1M | $12M | $25M | |
| Cash From Investing | -$13.8M | -$7.3M | -$7.2M | -$757K | -$1.1M | |
| Cash From Financing | $99.9M | $62.7M | -$66.3M | $416K | -$25.5M | |
| Free Cash Flow | -$99.4M | -$23.5M | $78.8M | $11.2M | $23.9M | |
ADMA
Sector
Market Cap
$4.2B
$38.4M
Price % of 52-Week High
75.76%
45.53%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.78%
1-Year Price Total Return
186.1%
-39.05%
Beta (5-Year)
0.605
0.774
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$17.28
200-day SMA
Buy
Level
$16.15
Bollinger Bands (100)
Buy
Level
15.95 - 19.71
Chaikin Money Flow
Sell
Level
-364.6M
20-day SMA
Buy
Level
$16.46
Relative Strength Index (RSI14)
Buy
Level
58.84
ADX Line
Sell
Level
19.34
Williams %R
Sell
Level
-13.8672
50-day SMA
Buy
Level
$16.78
MACD (12, 26)
Buy
Level
0.29
25-day Aroon Oscillator
Buy
Level
28
On Balance Volume
Neutral
Level
507.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (19.043)
Buy
CA Score
(Annual)
Level (1.9066)
Buy
Beneish M-Score
(Annual)
Level (-2.5159)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-4.5176)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
ADMA Biologics Inc is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics for the treatment of immunodeficient patients at risk for infection and others at risk for certain infectious diseases. The segments of the company are ADMA BioManufacturing which generates maximum revenue and Plasma Collection Centres, and corporate segment. The company sells plasma-derived intermediate fractions to certain customers, which are generated as part of its FDA-approved manufacturing process for IG and IVIG products. It also provides laboratory contracting services to certain customers and anticipates providing contract filling, labeling and packing services. The company derives maximum revenue from United States.
Stock Forecast FAQ
In the current month, ADMA has received 4 Buy ratings 0 Hold ratings, and 0 Sell ratings. The ADMA average analyst price target in the past 3 months is $25.27.
-
Where Will ADMA Biologics Stock Be In 1 Year?
According to analysts, the consensus estimate is that ADMA Biologics share price will rise to $25.27 per share over the next 12 months.
-
What Do Analysts Say About ADMA Biologics?
Analysts are divided on their view about ADMA Biologics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that ADMA Biologics is a Sell and believe this share price will drop from its current level to $19.09.
-
What Is ADMA Biologics's Price Target?
The price target for ADMA Biologics over the next 1-year time period is forecast to be $25.27 according to 4 Wall Street analysts, 4 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is ADMA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for ADMA Biologics is a Buy. 4 of 4 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ADMA?
You can purchase shares of ADMA Biologics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase ADMA Biologics shares.
-
What Is The ADMA Biologics Share Price Today?
ADMA Biologics was last trading at $18.24 per share. This represents the most recent stock quote for ADMA Biologics. Yesterday, ADMA Biologics closed at $17.91 per share.
-
How To Buy ADMA Biologics Stock Online?
In order to purchase ADMA Biologics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Tesla Stock: The Bear Case
The recent stock market drop has been a punishing time…
Is VUG a Good ETF to Buy?
For the last few years, earnings growth from the tech…
Stock Ideas
Sell
46
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 34x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 39x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.8T
P/E Ratio: 32x
Alerts
Sell
5
CABO alert for Mar 14
Cable One [CABO] is down 3.82% over the past day.
Sell
38
ADBE alert for Mar 14
Adobe [ADBE] is up 3.75% over the past day.
Sell
29
CAR alert for Mar 14
Avis Budget Group [CAR] is up 6.2% over the past day.
